Dabur Pharma Of India To Sell Majority Interest To Fresenius
This article was originally published in PharmAsia News
India's Dabur Pharma agreed to sell a nearly three-quarters interest in the company to Fresenius Kabi of Singapore. Fresenius Kabi is a subsidiary of Fresenius SE, a global company based in Germany. Darbur's founder and director, Anand Burman, said his company agreed to sell Fesenius a 73.27 percent interest because it needed to integrate with a global company capable of expanding the firm more quickly. He noted Dabur has been getting its drugs approved around the world and it would not have made sense to attempt to market them by itself. (Click here for more
You may also be interested in...
Brakes May Be Put On Direct MNC Deals In India As Government Fears Threat To The Indian Drug Industry
MUMBAI - Acquisition of growing Indian firms by global pharmaceutical companies may get tough in the coming days as the government is brainstorming about how to clamp restrictions on buying controlling equity stakes in Indian entities through the automatic foreign direct investment route (FDI)
MUMBAI - Having sold its generic oncology business to German infusion drugs and clinical nutrition company Fresenius Kabi, Dabur Pharma Founder Anand Burman is looking at a second source of value creation beyond generics
Third quarter earnings show Gilead’s Immunomedics buy paid off, but filgotinib’s path may narrow. The HIV and HCV franchises picked up from their COVID-19 lull.